US Bans Russian Kaspersky Software Amid Alleged Threatsby Lilu Anderson 21.06.2024"US bans Russian cybersecurity software Kaspersky over national security concerns and alleged influence operations, effective Sept. 30."
US to Ban Kaspersky Software Sales, Reports Indicateby Lilu Anderson 20.06.2024US to ban Kaspersky antivirus over national security risks, citing alleged Russian ties. Move prevents sales, aims to protect infrastructure.
Trinity Biotech Stock Rated “Buy” Amid Price Fluctuationsby Lilu Anderson 19.06.2024Trinity Biotech plc gets a "buy" rating from StockNews.com analysts, spotlighting potential for investors with a focus on its diagnostic ...
Rider Data Breach: TheBus & Handi-Van Websites Downby Lilu Anderson 19.06.2024Rider data compromised in TheBus and Handi-Van ransomware attack; OTS investigates, services disrupted but routes still operational, recovery ongoing.
Biotech Stocks: Potential Soar of 120% and 295%by Mark Eisenberg 25.04.2024Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Breakthrough Vaccine: One Shot Protects Against All Virus Strainsby Lilu Anderson 18.04.2024Researchers have successfully developed a single-dose vaccine that prompts the production of T-cells and "memory" B cells to fight against ...
Teladoc Health Vs. Novavax: Stock Picks and Avoidanceby Mark Eisenberg 09.04.2024Teladoc Health's revenue grew by 8% to $2.6 billion in 2023, with a gross margin of 70.8%. On the other ...
Pfizer and Moderna Stocks: Down 30% and 27% – Buy and Holdby Terry Bingman 06.04.2024Pfizer and Moderna have struggled in the stock market, but Pfizer has a substantial pipeline of programs. Moderna's success is ...
Vaccine Investment Urgency: Why Isn’t More Being Done?by Terry Bingman 30.03.2024Cancel subscription renewal anytime, pay upfront for a year and save 20%, and enjoy the FT digital service. Discover why ...
Moleculin Biotech Stock Coverage and Analysis at StockNewsby Mark Eisenberg 28.03.2024Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...